Lei Zhao, Mingya Zhang, Jiafu Zhou, Xinglong Jia, Xiaotong Liang, Minjia Tan* and Jun-Yu Xu*,
{"title":"激酶抑制剂治疗结直肠癌细胞的磷酸蛋白组学和乙酰组学特征","authors":"Lei Zhao, Mingya Zhang, Jiafu Zhou, Xinglong Jia, Xiaotong Liang, Minjia Tan* and Jun-Yu Xu*, ","doi":"10.1021/acsptsci.5c00398","DOIUrl":null,"url":null,"abstract":"<p >Kinase inhibitors have long been studied to be developed into therapeutic drugs or chemical probes, but their off-target effects in phosphoproteomics and acetylomics remain largely unexplored. Here, we provided a systematic molecular response to kinase inhibitors in the colorectal cancer cell line, including the proteomics, phosphoproteomics, and acetylomics. The results provided comprehensive kinase activity perturbations of each kinase inhibitor and presented unique pathway-level biological effects, mitochondrial functional perturbations, and kinase activity changes for inhibitors targeting the same pathway. Furthermore, we discovered the potential protein post-translational modification (PTM) crosstalk between lysine acetylation and protein phosphorylation. The study additionally proposed potential combination treatment strategies. In summary, this study presented in-depth and comprehensive analysis results of kinase inhibitor perturbations on the colorectal cancer cell line at proteomic, phosphoproteomic, and acetylomic landscapes.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 9","pages":"3269–3280"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phosphoproteomic and Acetylomic Characterization of Colorectal Cancer Cells Treated with Kinase Inhibitors\",\"authors\":\"Lei Zhao, Mingya Zhang, Jiafu Zhou, Xinglong Jia, Xiaotong Liang, Minjia Tan* and Jun-Yu Xu*, \",\"doi\":\"10.1021/acsptsci.5c00398\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Kinase inhibitors have long been studied to be developed into therapeutic drugs or chemical probes, but their off-target effects in phosphoproteomics and acetylomics remain largely unexplored. Here, we provided a systematic molecular response to kinase inhibitors in the colorectal cancer cell line, including the proteomics, phosphoproteomics, and acetylomics. The results provided comprehensive kinase activity perturbations of each kinase inhibitor and presented unique pathway-level biological effects, mitochondrial functional perturbations, and kinase activity changes for inhibitors targeting the same pathway. Furthermore, we discovered the potential protein post-translational modification (PTM) crosstalk between lysine acetylation and protein phosphorylation. The study additionally proposed potential combination treatment strategies. In summary, this study presented in-depth and comprehensive analysis results of kinase inhibitor perturbations on the colorectal cancer cell line at proteomic, phosphoproteomic, and acetylomic landscapes.</p>\",\"PeriodicalId\":36426,\"journal\":{\"name\":\"ACS Pharmacology and Translational Science\",\"volume\":\"8 9\",\"pages\":\"3269–3280\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Pharmacology and Translational Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsptsci.5c00398\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00398","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Phosphoproteomic and Acetylomic Characterization of Colorectal Cancer Cells Treated with Kinase Inhibitors
Kinase inhibitors have long been studied to be developed into therapeutic drugs or chemical probes, but their off-target effects in phosphoproteomics and acetylomics remain largely unexplored. Here, we provided a systematic molecular response to kinase inhibitors in the colorectal cancer cell line, including the proteomics, phosphoproteomics, and acetylomics. The results provided comprehensive kinase activity perturbations of each kinase inhibitor and presented unique pathway-level biological effects, mitochondrial functional perturbations, and kinase activity changes for inhibitors targeting the same pathway. Furthermore, we discovered the potential protein post-translational modification (PTM) crosstalk between lysine acetylation and protein phosphorylation. The study additionally proposed potential combination treatment strategies. In summary, this study presented in-depth and comprehensive analysis results of kinase inhibitor perturbations on the colorectal cancer cell line at proteomic, phosphoproteomic, and acetylomic landscapes.
期刊介绍:
ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered.
ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition.
Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.